Thursday, December 16, 2010
Genta Inc., of Berkeley Heights, N.J., received $5 million from a control account related to its $25 million private placement of convertible notes issued in March 2010. Proceeds will be used to determine survival data from Genta's Phase III trial of Genasense (oblimersen sodium) for melanoma and to accelerate development of other pipeline products.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.